Occupier

Find Out The Latest

Welcome to the latest news from The Oxford Science Park, where you can keep up to date with developments across our community. From company milestones and scientific breakthroughs to investment news, partnerships, events and Park announcements, discover how our occupiers are advancing innovation and shaping the future.

Media enquiries: comms@oxfordsp.com

Welcoming UK Agri-Tech Centre to The Oxford Science Park

01 Sep 2026

The Oxford Science Park is pleased to welcome the UK Agri-Tech Centre, which joined the Park earlier this year. The UK Agri-Tech Centre supports agri-tech companies to prove, build and scale technologies that address the challenges facing agriculture, horticulture and aquaculture. By connecting businesses with farmers, growers, researchers, investors and industry partners, it helps promising technologies move from development and testing... Read more

Scancell receives UK approval to begin Phase 3 melanoma trial

25 Aug 2026

Scancell, a clinical-stage immuno-oncology company based at The Oxford Science Park, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase 3 clinical trial of its lead cancer treatment, iSCIB1+, in patients with advanced melanoma. The trial is an important step towards potentially bringing iSCIB1+ to patients. It is expected to involve 550 people with advanced melanoma across around 90... Read more

Moa Technology announces £22.2m Series C funding

23 Jul 2026

Moa Technology has announced a £22.2 million Series C financing round, co-led by Oxford Science Enterprises and Supernova Invest. This new investment reflects the strength of Moa’s IP and the progress it has made to become the innovation partner of choice for the crop protection industry. In the last 24 months, Moa has formed R&D collaborations with four leading companies - Nufarm, Gowan, Certis Belchim and Corteva Agriscience – to develop... Read more

Oxford Vacmedix announce successful Phase 1 trial results for cancer

23 Apr 2026

Oxford Vacmedix , a biotech company developing novel immunotherapies to treat cancer, has announced the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer. This Phase 1 clinical trial of OVM-200 is a multicentre, open‑label,... Read more

Vivid Dx: an Oxford spinout racing the clock on sepsis

20 Apr 2026

In the fight against sepsis, speed is everything. Every hour without the right diagnosis increases the risk of death, yet in hospitals around the world, clinicians are still forced to wait days for answers. That stark reality is what drives Vivid Dx, a diagnostics company based at The Oxford Science Park that is transforming how bloodstream infections are detected and treated. The company is built on world-class University of Oxford research,... Read more

News